Actively Recruiting
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Led by TORL Biotherapeutics, LLC · Updated on 2026-02-13
90
Participants Needed
14
Research Sites
260 weeks
Total Duration
On this page
Sponsors
T
TORL Biotherapeutics, LLC
Lead Sponsor
T
Translational Research in Oncology
Collaborating Sponsor
AI-Summary
What this Trial Is About
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
CONDITIONS
Official Title
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Advanced solid tumor
- Measurable disease, per RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Adequate organ function
You will not qualify if you...
- Not recovered from acute toxicities of previous therapy except alopecia or certain lab abnormalities
- Received prior cancer treatments within 14 days (small molecule) or 28 days (biologic) before first dose of TORL-1-23
- Progressive or symptomatic brain metastases
- Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection
- History of significant cardiac disease
- History of myelodysplastic syndrome or acute myeloid leukemia
- History of another cancer within 3 years before study treatment, except certain treated skin cancers and low-risk malignancies
- Pregnant or breastfeeding if female
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
Providence Medical Foundation
Fullerton, California, United States, 92835
Actively Recruiting
2
UCLA - JCCC Clinical Research Unit
Los Angeles, California, United States, 90095
Actively Recruiting
3
University of Kentucky Medical Center
Lexington, Kentucky, United States, 40536
Actively Recruiting
4
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
5
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
6
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
7
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Actively Recruiting
8
Sarah Cannon Research Institute Texas Oncology
Tyler, Texas, United States, 75702
Actively Recruiting
9
Virginia Cancer Specialists
Fairfax, Virginia, United States, 22031
Actively Recruiting
10
St. Vincent's Hospital, The Catholic University of Korea
Suwon, Gyeonggi-do, South Korea, 16247
Actively Recruiting
11
Seoul National University Hospital
Seoul, South Korea, 03080
Actively Recruiting
12
Severance Hospital
Seoul, South Korea, 03723
Actively Recruiting
13
Asan Medical Center
Seoul, South Korea, 05505
Actively Recruiting
14
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
Research Team
N
Nora Ku, MD
CONTACT
I
Ibrahim Qazi
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here